126 related articles for article (PubMed ID: 21736524)
41. [Development of nanohydroxyapatite composites as bone grafting materials].
Wang R; Wen D; Xie X; Zhong Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Oct; 25(5):1231-4. PubMed ID: 19024483
[TBL] [Abstract][Full Text] [Related]
42. A 12 month in vivo study on the response of bone to a hydroxyapatite-polymethylmethacrylate cranioplasty composite.
Itokawa H; Hiraide T; Moriya M; Fujimoto M; Nagashima G; Suzuki R; Fujimoto T
Biomaterials; 2007 Nov; 28(33):4922-7. PubMed ID: 17707904
[TBL] [Abstract][Full Text] [Related]
43. Improvement in biocompatibility of ZrO2-Al2O3 nano-composite by addition of HA.
Kong YM; Bae CJ; Lee SH; Kim HW; Kim HE
Biomaterials; 2005 Feb; 26(5):509-17. PubMed ID: 15276359
[TBL] [Abstract][Full Text] [Related]
44. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement.
McLeod K; Anderson GI; Dutta NK; Smart RS; Voelcker NH; Sekel R; Kumar S
J Biomed Mater Res A; 2006 Nov; 79(2):271-81. PubMed ID: 16817191
[TBL] [Abstract][Full Text] [Related]
45. Preparation and characterization of nano-hydroxyapatite/chitosan composite scaffolds.
Kong L; Gao Y; Cao W; Gong Y; Zhao N; Zhang X
J Biomed Mater Res A; 2005 Nov; 75(2):275-82. PubMed ID: 16044404
[TBL] [Abstract][Full Text] [Related]
46. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair.
Shi X; Wang Y; Ren L; Zhao N; Gong Y; Wang DA
Acta Biomater; 2009 Jun; 5(5):1697-707. PubMed ID: 19217361
[TBL] [Abstract][Full Text] [Related]
47. Solubility of hydroxyapatite/mica composites.
Nordström EG; Hara T; Herø H
Biomed Mater Eng; 1996; 6(2):73-8. PubMed ID: 8761517
[TBL] [Abstract][Full Text] [Related]
48. Quercetin and alendronate multi-functionalized materials as tools to hinder oxidative stress damage.
Forte L; Torricelli P; Boanini E; Rubini K; Fini M; Bigi A
J Biomed Mater Res A; 2017 Dec; 105(12):3293-3303. PubMed ID: 28865182
[TBL] [Abstract][Full Text] [Related]
49. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
50. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections.
Rauschmann MA; Wichelhaus TA; Stirnal V; Dingeldein E; Zichner L; Schnettler R; Alt V
Biomaterials; 2005 May; 26(15):2677-84. PubMed ID: 15585271
[TBL] [Abstract][Full Text] [Related]
51. Three-dimensional composites manufactured with human mesenchymal cambial layer precursor cells as an alternative for sinus floor augmentation: an in vitro study.
Turhani D; Watzinger E; Weissenböck M; Yerit K; Cvikl B; Thurnher D; Ewers R
Clin Oral Implants Res; 2005 Aug; 16(4):417-24. PubMed ID: 16117765
[TBL] [Abstract][Full Text] [Related]
52. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
[TBL] [Abstract][Full Text] [Related]
53. Sequential dual-drug delivery of BMP-2 and alendronate from hydroxyapatite-collagen scaffolds for enhanced bone regeneration.
Lee D; Wufuer M; Kim I; Choi TH; Kim BJ; Jung HG; Jeon B; Lee G; Jeon OH; Chang H; Yoon DS
Sci Rep; 2021 Jan; 11(1):746. PubMed ID: 33436904
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the osteoconductivity of α-tricalcium phosphate, β-tricalcium phosphate, and hydroxyapatite combined with or without simvastatin in rat calvarial defect.
Rojbani H; Nyan M; Ohya K; Kasugai S
J Biomed Mater Res A; 2011 Sep; 98(4):488-98. PubMed ID: 21681941
[TBL] [Abstract][Full Text] [Related]
55. Fabrication and characterization of needle-like nano-HA and HA/MWNT composites.
Meng YH; Tang CY; Tsui CP; Chen DZ
J Mater Sci Mater Med; 2008 Jan; 19(1):75-81. PubMed ID: 17577639
[TBL] [Abstract][Full Text] [Related]
56. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
57. Development of an oral microemulsion formulation of alendronate: effects of oil and co-surfactant type on phase behaviour.
Karamustafa F; Celebi N
J Microencapsul; 2008 Aug; 25(5):315-23. PubMed ID: 18465302
[TBL] [Abstract][Full Text] [Related]
58. Antiresorptive properties of strontium substituted and alendronate functionalized hydroxyapatite nanocrystals in an ovariectomized rat spinal arthrodesis model.
Salamanna F; Giavaresi G; Parrilli A; Torricelli P; Boanini E; Bigi A; Fini M
Mater Sci Eng C Mater Biol Appl; 2019 Feb; 95():355-362. PubMed ID: 30573259
[TBL] [Abstract][Full Text] [Related]
59. In-situ dispersed photopolymerization of cyclic acetals/hydroxyapatite composites: effects of the content of hydroxyapatite.
Yin R; Wu W; Wang K; Zhang WJ
Mater Sci Eng C Mater Biol Appl; 2015 Jan; 46():239-45. PubMed ID: 25491983
[TBL] [Abstract][Full Text] [Related]
60. The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats.
Hedvičáková V; Žižková R; Buzgo M; Vištejnová L; Klein P; Hovořáková M; Bartoš M; Steklíková K; Luňáčková J; Šebová E; Paurová I; Rysová M; Filová E; Rampichová M
Int J Nanomedicine; 2023; 18():541-560. PubMed ID: 36756052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
